October 7th 2024
A poster presented at the EADV Congress revealed the drug's long-term efficacy in treating AD, particularly in the head and neck regions.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Expert Insights: Unmet Needs in Topical Treatment for Atopic Dermatitis
April 12th 2024Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.
Expanding on Atopic Dermatitis Triggers and Comorbidities, and Advancements
April 5th 2024Mark Lebwohl, MD, discusses the rapid expansion of therapeutic options, including targeted drugs like JAK inhibitors and IL-13 treatments for atopic dermatitis, paralleling the progress seen in psoriasis treatment over the last decade.
Understanding The Heterogenous Nature of Atopic Dermatitis
April 5th 2024Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.
The AD Journey of a Construction Worker: Insights from a 38-Year-Old Caucasian Male
April 5th 2024Alexandra Golant, MD, presents the case of a 38-year-old Caucasian male construction worker, diagnosed with moderate AD at age 15, and his treatment history with various interventions and physician referral considerations.
Disease Severity's Influence on Atopic Dermatitis Therapeutic Selection
April 5th 2024Dr. Golant discusses the role of disease severity in her selection of atopic dermatitis treatments, particularly noting the characterization of hand and foot involved patients as often moderate cases, and highlighting the rapid response observed in these areas when treated.
Barrier Function and Atopic Dermatitis
March 29th 2024A dermatology expert reviews the role of barrier function in AD and outlines available treatments, emphasizing the importance of moisturizing and rapid options when appropriate, as well as the efficacy of rapid systemic treatments in patients when appropriate.
Top Considerations From Latest AAD AD Guidelines
March 26th 2024Raj Chovatiya, MD, PhD, gives an overview of what all clinicians need to know about the updated atopic dermatitis guidelines published by the American Academy of Dermatology including approaches with systemic therapies, which therapeutic modalities to prioritize, and patient considerations to guide decision-making.